trending Market Intelligence /marketintelligence/en/news-insights/trending/br7ftdgs7clpp0szej8rla2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

ViiV Healthcare's 2-drug HIV-1 pill gets EU marketing nod

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


ViiV Healthcare's 2-drug HIV-1 pill gets EU marketing nod

London's ViiV Healthcare Ltd. said the European Commission granted marketing authorization to Juluca for treating certain patients with HIV-1 infection.

Juluca is a 2-drug, single pill regimen which brings together ViiV's dolutegravir, known in single-tablet form as Tivicay, and rilpivirine, sold individually as Edurant by Johnson & Johnson.

SNL Image

The authorization comes almost a month after the European Medicines Agency's Committee for Medicinal Products for Human Use granted a positive opinion to the therapy. Juluca is already approved in the U.S. and Canada.

Juluca aims to address pill fatigue, a problem among HIV patients who often take multiple medications a day.

ViiV's Juluca is the first treatment with a reduced-drug regimen to reach the market for HIV-1 patients, outracing its rival Gilead Sciences Inc.

ViiV Healthcare was established in November 2009 by GlaxoSmithKline PLC, which holds a majority stake in the company, and Pfizer Inc.

Japan's Shionogi & Co. Ltd. is also a shareholder in ViiV.